Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)

Next Previous
Trial Profile

Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms Saci-IO-HR

Most Recent Events

  • 04 Jun 2024 Results assessing safety and efficacy of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 07 May 2024 According to a Gilead Sciences media release, data from this trial to be presented in abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 01 Mar 2024 Planned primary completion date changed from 1 Jun 2025 to 9 Mar 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top